Oppenheimer says . . . "The company announced several employees mishandled R&D test data and results, rendering all previously announced data unreliable." :eek:
You guys might want to check out Exact Sciences (EXAS) at $1.70 per share given that SQNM tried to buy them out on the cheap a couple of months ago because it looked as though SQNM was "trampling" on Exact's patent portfolio for invitro testing. EXAS turned down SQNM's $1.50 per share offer back in January and instead, welcomed a strategic $24.5 MILLION DOLLAR deal with Genzyme (GENZ). EXAS is currently working on getting a non-invasive colorectal cancer screening lab test FDA approved and to the market, but owns numerous patents in molecular diagnostics. They just replaced their management team with the CEO and CFO from Third Wave Technologies ( creator of the HPV test ). Third Wave was recently acquired by Hologic for $582 million last year.
The way SQNM moved to day it seems the bottom is in. I read all the available articles and believe that if we hold long SQNM will go much higher later on. Small float can be manipulated easily.
Nice profit if we accumulated since $3....Good sign that it's above the bottom part of gap. Next resistance is $5 then $6.24..will see...